Why Oncolytic Virotherapy is Rapidly Gaining Interest Among Oncology Researchers:

• Broad Viral Platforms – Both DNA-based (adenovirus, poxvirus, herpes simplex virus) and RNA-based (VSV, coxsackie virus, reovirus, NDV, measles virus) platforms are under investigation for clinical applications.
• Selective Tumor Infection – Oncolytic viruses specifically target and infect tumor cells while sparing healthy tissues.
• Replication & Spread in Tumors – Oncolytic viruses rely on tumor-specific factors, such as p53 mutations, Wnt/beta-catenin signaling, and defective type I IFN pathways, to replicate and propagate within the tumor.
• Immune System Activation – Beyond direct tumor destruction, oncolytic viruses reshape the tumor microenvironment to enhance immune recognition and anti-tumor responses

EPO has a strong track record in preclinical research on oncolytic virotherapy, with extensive experience in both standalone and combination approaches.

Our Expertise Includes:

• Oncolytic Virus Evaluation – Assessing the efficacy of oncolytic viruses across a range of solid tumor models.
• Combinatorial In Vivo Studies – Investigating the synergy between oncolytic virotherapy and immunotherapies, particularly immune checkpoint inhibitors.

• Immune Response Analysis – Conducting in vitro and in vivo assays to measure the impact of oncolytic viruses on anti-tumor T and B cell activity.

Supporting Oncovita’s Measles Virus-Based Therapy

A recent collaboration with Oncovita highlights EPO’s role in advancing oncolytic virotherapy. Our PDX models were instrumental in evaluating Oncovita’s measles virus-based candidate, MVdeltaC, demonstrating robust viral oncolysis and immune engagement.

For more details, or to discuss potential collaborations, please contact Turn on Javascript!. We look forward to advancing your oncolytic virotherapy research with our knowledge and expertise.

Best regards,
Jens Hoffmann (CEO), Wolfgang Walther (CSO), and Antje Wengner (CSO)
EPO Berlin-Buch